Gastric Preparation of Magnetic-controlled Capsule Endoscopy

Sponsor
Changhai Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02846155
Collaborator
(none)
120
2
3
7
60
8.5

Study Details

Study Description

Brief Summary

By using three different Gastric Preparation of Magnetic-controlled Capsule Endoscopy, the investigators hope to find out the optimal gastric preparation plan.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

It is a prospective, single-blind, randomized controlled trial. Patients who were conducted by Magnetic-controlled Capsule Endoscopy at Changhai Hospital will be randomly allocated into three different Gastric Preparation group before the procedure. It include clear water group which patient only drink 1000ml clear water before checking; simethicone group which patient drink 950ml clear water and 15ml simethicone before checking; simethicone combined with pronase group which patient drink 900ml lear water and 15ml simethicone and 20,000iu pronase before checking. The result were got from a relevant professional physician's blinded independent image-reading.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial
Study Start Date :
May 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: clear water group

the patients only drink 1000ml clear water before checking

Other: clear water
the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination

Experimental: simethicone group

the patients drink 950ml clear water and 15ml simethicone before checking

Drug: simethicone
the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination

Experimental: simethicone combined with pronase group

the patients drink 900ml clear water and 15ml simethicone and 20,000iu pronase before checking

Drug: simethicone combined with pronase
the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion),pronase granules(Deyou;Beijing Tide Pharmaceutical Co,China,containing 20,000iu pronase),and clear water before Magnetic-controlled Capsule Endoscopy examination

Outcome Measures

Primary Outcome Measures

  1. the level of gastric cleansing [4 month]

    Two investigators who did not know which kind of gastric preparation of the patient scored the level of gastric cleansing 0f 120 participants according to a four-point grading scale: poor, fair, good, and excellent,which was pointed 3,2,1,and 0.The investigators should evaluate the gastric cleansing of six anatomical landmarks (cardia, fundus, body, angulus, antrum and pylorus).A poor level of cleansing indicated the mucosa was obscured largely by a lot of air bubbles and grume,fair indicated that a portion of the mucosa was obscured by air bubbles and grume that was enough to prevent a reliable visualization of polyps, good indicated that a small amount of air bubbles and grume,and excellent indicated that the fluid was clear and the image was either free or had only small bits of air bubbles and grume.

Secondary Outcome Measures

  1. Transit time [4 month]

    include gastric transit time,smal bowel transit time

  2. Diagnostic yield of Magnetic-controlled Capsule Endoscopy [4 month]

    The gastric focal lesion was defined as any of the positive findings including polyp, ulcers, submucosal tumor (SMT) and others (i.e. xanthoma, diverticulum, etc.). Erosion, gastritis and gastric atrophy were defined as negative findings, because they are diffuse lesions which can be easily diagnosed by Magnetic-controlled Capsule Endoscopy.

  3. Tolerability of participants [4 month]

    The endoscopist scored the tolerability of participants according to a three-point grading scale: poor, fair, and excellent,which was pointed 2,1,and 0.A poor tolerability of participants indicated patients with perforated severe abdominal pain,nausea, vomiting,etc.fair indicated patients with perforated little abdominal pain,nausea, vomiting.and excellent indicated that patients with no obvious discomfort.

  4. the visibility of gastric [4 month]

    Two investigators scored the level of gastric visibility 0f 120 participants according to a four-point grading scale: poor, fair, good, and excellent,which was pointed 3,2,1,and 0.The investigators should evaluate the visibility of gastric of six anatomical landmarks (cardia, fundus, body, angulus, antrum and pylorus).A poor level of cleansing indicated the less than 50% of mucosa could be seen,fair indicated that 50%-75% of the mucosa could be seen, good indicated that more than 75% of the mucosa could be seen,and excellent indicated the whole mucosa could be seen.

  5. the time of gastric examination [4 month]

    the time indicated since the first gastric mucosal image was observed to the endoscopist completed the whole gastric examination。

  6. the added amount of water of the whole process during gastric examination [4 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult patients aged 16-75 years, who were scheduled to undergo a Magnetic-controlled Capsule Endoscopy, were eligible for this study.
Exclusion Criteria:
  • Dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal stenosis, overt gastrointestinal bleeding, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy, or postabdominal radiation;

  • Congestive heart failure, renal insufficiency, under therapeutic anticoagulation, in poor general condition (American Society of Anesthesiologists class III/IV), claustrophobia, metallic parts, a pacemaker or other implanted electromedical devices, artificial heart valves;

  • Pregnancy or suspected pregnancy;

  • Exclusion criteria for standard magnetic resonance imaging (MRI) examination such as the presence of surgical metallic devices, even though its low magnetic field would technically not interfere with such devices;

  • Currently participating in another clinical study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Changhai Hospital Shanghai China
2 Changhai Hospital Shanghai China

Sponsors and Collaborators

  • Changhai Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhuan Liao, M.D., Associate Professor, Associate Chief Physician, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT02846155
Other Study ID Numbers:
  • 20160410A
First Posted:
Jul 27, 2016
Last Update Posted:
Jul 27, 2016
Last Verified:
Jul 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Zhuan Liao, M.D., Associate Professor, Associate Chief Physician, Changhai Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2016